Concepedia
Statistics
Publications
32
Citations
2.7K
H-Index
23
Active since
1989
Affiliations
Roche Pharma AG (Germany)(Current)
Heidelberg University
Roche (Switzerland)
Pharmalog (Germany)
Oslo University Hospital
Max Hasmann is an author at Roche Pharma AG (Germany) specializing in medicine, cell biology, and tumor biology.
Top concepts
MedicineCell BiologyPharmacologyTumor BiologyImmunologyBreast CancerCancer BiologyCancer TherapyCancer ResearchOncology
Publications per year
1989–2021
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Max Hasmann, Isabel Schemainda · PubMed · 2003 · 634 citations
Natural Precursor Nicotinamide, Apoptosis, Cell Death +18
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer, Thomas Friess, Helmut Burtscher et al. · Cancer Research · 2009 · 617 citations · Full text
Breast Oncology, Immunology, Tumor Biology +17
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi, Marc Cinci, Max Hasmann et al. · Molecular Oncology · 2013 · 106 citations · Full text
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Thomas Friess, Werner Scheuer, Max Hasmann · Clinical Cancer Research · 2005 · 95 citations
Immunology, Pathology, Pharmacotherapy +17
Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy
Manickam Muruganandham, Alan Alfieri, Cornelia Matei et al. · Clinical Cancer Research · 2005 · 90 citations
1–5 of 32